Community protocol
Third-partyKisspeptin 10mg
- 01Reconstitution solution
- 2.5 mL
- 02Dose
- 0.2 mg
- 03Syringe units
- 5 units
- 04Frequency
- 3x/week
- 05Cycle length
- 90 days
- 06Bacteriostatic water
- 2.5 mL
- 07Bottle size
- 10 mg
- 08Bottles needed
- 1
Kisspeptin-10
A reproductive-axis neuropeptide with a substantial body of controlled human physiology studies, mostly from a single UK research programme. Not approved; used clinically only in research settings.
Overview
Kisspeptin sits at the top of the reproductive hormone chain. It signals the hypothalamus to release GnRH, which in turn drives LH and FSH from the pituitary, which then drive testosterone or oestrogen. It was discovered because people born without a working kisspeptin receptor do not go through puberty. In human studies it has been used to trigger ovulation in IVF and to probe how the reproductive axis is regulated.
Kisspeptin-10 is the C-terminal decapeptide of kisspeptin-54, the shortest fragment retaining full agonist activity at KISS1R (GPR54). The receptor is Gq/11-coupled; activation drives PLC-beta, IP3-mediated calcium mobilization, and PKC activation in hypothalamic GnRH neurons, depolarizing them and increasing GnRH pulse generation. Kisspeptin neurons in the arcuate nucleus co-express neurokinin B and dynorphin (KNDy neurons) and constitute the GnRH pulse generator itself, with NKB providing the excitatory and dynorphin the inhibitory limb of the pulse cycle. Kisspeptin neurons are also the principal site of oestrogen negative and positive feedback, since GnRH neurons themselves largely lack ERα. Because kisspeptin acts upstream of GnRH, it produces a physiological rather than supraphysiological LH surge, which is the basis for its investigation as an IVF trigger with lower ovarian hyperstimulation risk.
Research areas
Reproductive endocrinologyFertilityNeuroendocrineSexual function
Community-specified data
Community dosage information
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Dosing reported in the literature
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Intravenous bolus of 0.3 nmol/kg kisspeptin-10 in healthy male physiology studiesPhysiology probe, not a therapeutic protocol. | Dhillo et al., Journal of Clinical Endocrinology & Metabolism 2005 |
| Single subcutaneous kisspeptin-54 doses of 1.6 to 12.8 nmol/kg as an IVF oocyte maturation triggerThis used kisspeptin-54, not the KP-10 fragment; the two differ in half-life. | Jayasena et al., Journal of Clinical Investigation 2014 |
Trial status
Multiple completed controlled human physiology studies and phase 2 trials in IVF triggering. No phase 3 programme.
Discovery of function
CompletedLoss-of-function mutations in GPR54 were identified as a cause of idiopathic hypogonadotropic hypogonadism, establishing kisspeptin as essential for puberty.
Human physiology studies
CompletedControlled studies in healthy men and women established dose-dependent LH release and mapped the compound's role in the reproductive axis.
Phase 2 — IVF oocyte maturation trigger
Completed53 women undergoing IVF received kisspeptin-54 as an oocyte maturation trigger. Mature oocytes were retrieved across all dose groups with live births reported.
Reported safety signals
- Consistently well tolerated across published human studies at physiological doses.
- Continuous rather than pulsatile exposure causes KISS1R desensitization and paradoxically suppresses the axis — dosing pattern matters more than dose magnitude.
- No long-term human exposure data exist.
Primary sources
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →